FMP
ALPS Medical Breakthroughs ETF
SBIO
AMEX
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
31.59 USD
-0.214 (-0.677%)
About
ceo
N/A
sector
Financial Services
industry
Asset Management
website
N/A
exchange
AMEX
Description
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
CIK
0001414040
ISIN
US00162Q5936
CUSIP
00162Q593
Address
N/A
Phone
NA
Country
US
Employee
N/A
IPO Date
Dec 31, 2014
Key Executives
